Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes
Diabetes Care · 01.02.2023 · 46 (2) · 391-398
DOI: 10.2337/dc22-1287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 08.12.2022. Verfasst von Kevin Ni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Service-Endocrinology, Denver Health, Denver, CO. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH/NHLBI, USA, Robert Wood Johnson Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Current studies on continuous glucose monitor (CGM) uptake are revealing for significant barriers and inequities for CGM use among patients from socially underprivileged communities. This study explores the effect of full subsidies regardless of diabetes type on CGM uptake and HbA1c outcomes in a U.S. adult patient population on Medicaid. RESEARCH DESIGN AND METHODS This retrospective cohort study examined 3,036 adults with diabetes enrolled in a U.S. Medicaid program that fully subsidized CGM. CGM uptake and adherence were assessed by CGM prescription and dispense data, including more than one fill and adherence by medication possession ratio (MPR). Multivariate logistic regression evaluated predictors of CGM uptake. Pre- and post-CGM use HbA1c were compared. RESULTS CGM were very well received by both individuals with type 1 diabetes and individuals with type 2 diabetes with similar high fill adherence levels (mean MPR 0.78 vs. 0.72; P = 0.06). No significant difference in CGM uptake outcomes were noted among major racial/ethnic groups. CGM use was associated with improved HbA1c among those with type 2 diabetes (−1.2% [13.1 mmol/mol]; P < 0.001) that was comparable between major racial/ethnic groups and those with higher fill adherence achieved greater HbA1c reduction (−1.4% [15.3 mmol/mol]; P < 0.001) compared with those with lower adherence (−1.0% [10.9 mmol/mol]; P < 0.001). CONCLUSIONS CGM uptake disparities can largely be overcome by eliminating CGM cost barriers. CGM use was associated with improved HbA1c across all major racial/ethnic groups, highlighting broad CGM appeal, utilization, and effectiveness across an underprivileged patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicine Service-Endocrinology, Denver Health, Denver, CO.
- Department of Medicine, University of Colorado, Aurora, CO.
ORCID-Profile: Rocio I Pereira
Förderung
- NHLBI NIH HHS
- NIH/NHLBI, USA
- Robert Wood Johnson Foundation
- Denver Health DOM AEF
Zitieren
APA
Ni, K., Tampe, C. A., Sol, K., Richardson, D. B., & Pereira, R. I. (2023). Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes. Diabetes Care, 46(2), 391-398. https://doi.org/10.2337/dc22-1287
Vancouver
Ni K, Tampe CA, Sol K, Richardson DB, Pereira RI. Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes. Diabetes Care. 2023;46(2):391-398. doi:10.2337/dc22-1287
BibTeX
@article{Ni2023,
author = {Ni, Kevin and Tampe, Carolyn A and Sol, Kayce and Richardson, Douglas B and Pereira, Rocio I},
title = {Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes},
journal = {Diabetes Care},
year = {2023},
volume = {46},
number = {2},
pages = {391--398},
doi = {10.2337/dc22-1287}
}
EUVIMED